Home › Funds › PSP Research LLC › GLUE

PSP Research LLC position in GLUE

MONTE ROSA THERAPEUTICS INC · Health Care

PSP Research LLC reported holding 23,000 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$557K, representing 0.30% of its reported portfolio and ranking #11 among its reported holdings. PSP Research LLC has disclosed GLUE holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)23.00K sh
Reported value held$556.60K
Portfolio Weight0.30%
First reportedQ1 2026
Last changeNew

How PSP Research LLC's GLUE position evolved

PSP Research LLC first disclosed a stake in GLUE in Q1 2026 at 28,000 shares (US$461K). The position peaked in Q2 2026 at 23,000 shares, worth US$557K. Across 2 filings, PSP Research LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 23,000 shares valued at US$557K.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 28.00K $460.60K New
Q2 2026 23.00K $556.60K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GLUE and 13F data

GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), TCG Crossover Management, LLC (US$111.9M), Vestal Point Capital, LP (US$111.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GLUE

All GLUE fund holders →